Cleared Traditional

K971006 - LYME DISEASE B. BURGDORFERI GENOGROUP 1 WESTERN BLOT IGG (WB0400G)

K971006 is an FDA 510(k) clearance for LYME DISEASE B. BURGDORFERI GENOGROUP 1..., manufactured by Mrl Diagnostics. The device is a Class 2 Microbiology device with product code LSR cleared through the Traditional 510(k) pathway after a 439-day FDA review.

K971006 · Mrl Diagnostics · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1998
Decision
439d
Days
Class 2
Risk

K971006 is an FDA 510(k) clearance for the LYME DISEASE B. BURGDORFERI GENOGROUP 1 WESTERN BLOT IGG (WB0400G). Classified as Reagent, Borrelia Serological Reagent (product code LSR), Class II - Special Controls.

Submitted by Mrl Diagnostics (Cypress, US). The FDA issued a Cleared decision on June 1, 1998 after a review of 439 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3830 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Microbiology submissions.

View all Mrl Diagnostics devices

FDA 510(k) Submission Details - K971006

510(k) Number K971006 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 19, 1997
Decision Date June 01, 1998
Days to Decision 439 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
337d slower than avg
Panel avg: 102d · This submission: 439d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

LSR Device Classification - Class 2, Special Controls

Product Code LSR Reagent, Borrelia Serological Reagent
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3830
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - LSR Reagent, Borrelia Serological Reagent

All 83
Devices cleared under the same product code (LSR) and FDA review panel - the closest regulatory comparables to K971006.
PREVUE(TM) BORRELIA BURGDORFERI ANTIBODY DETECTION ASSAY
K981913 · Chembio Diagnostic Systems, Inc. · Feb 1999
IS BORRELIA BURGDORFERI IGG/IGM ELISA TEST SYSTEM
K983605 · Columbia Bioscience, Inc. · Dec 1998
IS BORRELIA BURGDORFERI IGM TEST SYSTEM
K983606 · Columbia Bioscience, Inc. · Dec 1998
LYME DISEASE B. BURGDORFERI GENOGROUP 1 WESTERN BLOT IGM (WB0400M)
K971007 · Mrl Diagnostics · Jun 1998
LIMITED HUMAN LYME IGG WESTERN BLOT KIT (CAMBRIDGE DIAGNOSTICS IRELAND)
K970761 · Cambridge Diagnostics Ireland, Ltd. · Apr 1998
HUMAN LYME IGM WESTERN BLOT KIT
K970768 · Cambridge Diagnostics Ireland, Ltd. · Apr 1998